VPA22664/140/002

Moxiclear 100 mg + 25 mg spot-on solution for medium dogs

| Variation | Summary | Date |
|--------------|---|----------|
| Vet - C10 a) | VNRA - Vet - C10 a) - a) Administrative information concerning the holder's representative - C10 a) Changes to the safety, efficacy and pharmacovigilance part of the dossier: Changes to the labelling or the package leaflet which shall not be connected with the SPC: — administrative information concerning the holder's representative | 24/11/23 |
| Vet - B12 a) | VNRA - Vet - B12 a) - a) Minor changes to an approved test procedure (active, finished product, packaging, measuirng device) - B12 a) Changes to the quality part of the dossier: Minor changes — | 11/08/23 |
| Vet - B22 | VNRA - Vet - B22 - Change to importer, batch control arrangements and quality testing (replacement or addition of a site) for a finished product - B22 Changes to the quality part of the dossier: Change to importer, batch control arrangements and quality testing (replacement or addition of a site) for a finished product | 11/08/23 |
| Vet - C6 | VNRA - Vet - C6 - Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17 - C6 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17 | 19/07/23 |
| Vet - B46 | VNRA - Vet - B46 - Submission of a new or updated Ph. Eur. TSE CEP for a non- sterile active substance, starting material, reagent or intermediate, excipient - B46 Changes to the quality part of the dossier: Submission of a new or updated Ph. Eur. TSE CEP for a non- sterile: — active substance; — starting material, reagent, intermediate used in the manufacturing process of the active substance; — excipient | 23/01/23 |